Federal Register #DEA-1772

DEA Review of Importer Registration for Controlled Substances by Fisher Clinical Services, Inc.

This opportunity involves the Drug Enforcement Administration (DEA) reviewing an application from Fisher Clinical Services, Inc. to import controlled substances for clinical trials. - Government Buyer: - Drug Enforcement Administration (DEA), U.S. Department of Justice - OEMs and Vendors: - Fisher Clinical Services, Inc. (applicant/importer) - Products/Services Requested: - Importation of basic classes of controlled substances for clinical trial use only - Substances include: - Marihuana Extract (drug code 7350) - Marihuana (7360) - Tetrahydrocannabinols (7370) - 3,4-Methylenedioxymethamphetamine (7405) - 5-Methoxy-N-NDimethyltryptamine (7431) - Dimethyltryptamine (7435) - Psilocybin (7437) - Methylphenidate (1724) - Levorphanol (9220) - Noroxymorphone (9668) - Tapentadol (9780) - Unique or Notable Requirements: - Importation is strictly limited to clinical trial purposes - No authorization for commercial sale or importation of finished dosage forms - DEA is seeking public comments or objections regarding the application - Technical Information: - Each substance is identified by a specific DEA drug code - Registration does not permit other activities beyond clinical trial importation

Description

Fisher Clinical Services, Inc. has applied to be registered as an importer of basic classes of controlled substances. The application is a notice of application and includes a list of controlled substances for which the company seeks registration. The company plans to import these substances for clinical trials only, with no other activities authorized. Interested parties may submit electronic comments or objections and request a hearing by October 26, 2026.

View original listing